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Background
Chemotherapy resistance, either innate or acquired
requires for its development, expression changes on a
large number of genes therefore, it has been hypothesized
that epigenetic-mediated changes could be the driving
force for chemotherapy resistance. Aberrant DNA methyl-
ation and histone deacetylation are the main epigenetic
alterations in cancer, hence we hypothesized that hydrala-
zine, a DNA methylation inhibitor and valproate, a his-
tone deacetylase inhibitor may overcome resistance in
refractory solid tumors.
Methodology
This is a MinExpSize 2-stage phase II open-label, single-
arm study in which patients with advanced solid tumors
who were progressing at the second or third cycle of first,
second, third, fourth or fifth line of palliative chemother-
apy were included. Patients were typed for acetylator phe-
notype and then treated with hydralazine at a daily dose
of 182 mg for rapid or 83 mg for slow-acetylators, and
magnesium valproate at 40 mg/kg. Both drugs were
started at day -7 and continued until chemotherapy
ended. Chemotherapy consisted of the same pre-study
protocol regimen on which patients progressed. Response
and toxicity were evaluated.
Main findings
From a total of 27 patients that signed informed consent,
17 patients were evaluable for toxicity and 15 patients for
response. The primary sites in the 15 evaluable patients
were cervix (3), breast (3), lung (1), testis (1) and ovarian
(7) carcinomas. A clinical benefit (complete response,
partial response or disease stabilization) was observed in
12 (80%) patients, 4 partial responses and 8 stable dis-
ease. The treatment was well tolerated even though the
studied population was heavily pretreated. The most sig-
nificant toxicity was hematological. Grade 3 and 4 toxici-
ties were anemia, neutropenia, leukopenia and
thrombocytopenia in 23.5%, 41.1%, 47% and 35.2%
respectively. The main non-hematological toxicity was
drowsiness, mostly grade 2. The median survival was 6
months.
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Conclusion
Hydralazine and magnesium valproate are able to over-
come chemotherapy resistance in a heavily treated patient
population. The obtaining of partial responses and dis-
ease stabilization regardless of the tumor type and chem-
otherapy schedule strongly supports the concept that
epigenetic agents can erase the epigenetic mark associated
with the chemoresistant phenotype of cancer cells. These
results are in line with our observations in breast and cer-
vical cancer patients that hydralazine and valproate can
up-regulate a huge number of tumor suppressor genes.
Thus, epigenetic therapy with hydralazine and valproate
can be added to the armamentarium for cancer therapy.